INCY
Incyte Corporation · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth -5.3% ·
share flow +1.1% ·
net new positions -5.6%
· formula
Concentrated accumulation: rising shares among fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q1 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 3 | 0 | 433.49K | $48.73M | n/a | −2 |
| Q2 2026 | 154 | 0 | 131.73M | $14.93B | +4 | −5 |
| Q1 2026 | 158 | +1 | 132.61M | $12.47B | +5 | −5 |
| Q4 2025 | 156 | -1 | 139.13M | $13.74B | +1 | −1 |
| Q3 2025 | 24 | 0 | 89.63M | $7.60B | n/a | −1 |
| Q2 2025 | 22 | +1 | 88.20M | $6.01B | +1 | n/a |
| Q1 2025 | 18 | -1 | 44.33M | $2.68B | n/a | −1 |
| Q4 2024 | 19 | +1 | 43.85M | $3.03B | +1 | n/a |
| Q3 2024 | 17 | 0 | 35.50M | $2.35B | +1 | −1 |
| Q2 2024 | 17 | n/a | 33.47M | $2.03B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Dodge & Cox ✦ | 14.86M | -0.4% | $900.04M | 0.5% | ▼ Trim | 4 | SEC ↗ |
| 2 | State Street Global Advisors ✦ (passive) | 10.04M | 0.0% | $607.65M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 3 | AQR Capital Management ✦ | 6.74M | +92.3% | $405.79M | 0.4% | ▲ Add | 4 | SEC ↗ ×6 |
| 4 | Geode Capital Management ✦ (passive) | 4.21M | +4.2% | $254.01M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 5 | Renaissance Technologies ✦ | 3.71M | -9.2% | $224.56M | 0.3% | ▼ Trim | 4 | SEC ↗ |
| 6 | Norges Bank ✦ (passive) | 1.36M | -23.1% | $82.15M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 7 | D. E. Shaw & Co. ✦ | 862.60K | +49.6% | $52.23M | 0.1% | ▲ Add | 4 | SEC ↗ ×2 |
| 8 | Bridgewater Associates ✦ | 627.73K | -6.6% | $38.01M | 0.2% | ▼ Trim | 4 | SEC ↗ |
| 9 | T. Rowe Price ✦ | 477.04K | -47.8% | $28.89M | 0.0% | ▼ Trim | 4 | SEC ↗ ×2 |
| 10 | Point72 Asset Management ✦ | 342.01K | -73.2% | $20.71M | 0.1% | ▼ Trim | 3 | SEC ↗ |
| 11 | Arrowstreet Capital ✦ | 340.56K | +26.7% | $20.62M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 12 | Millennium Management ✦ | 332.03K | -39.2% | $20.10M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 13 | ARK Investment Management ✦ | 168.11K | +3.9% | $10.18M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 14 | Gotham Asset Management ✦ | 113.53K | +46.8% | $6.87M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 15 | Wellington Management ✦ | 80.88K | -40.7% | $4.90M | 0.0% | ▼ Trim | 4 | SEC ↗ ×2 |
| 16 | Two Sigma Investments ✦ | 56.98K | +103.2% | $3.45M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 17 | Fisher Asset Management ✦ | 17.14K | -40.8% | $1.04M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 18 | Citadel Advisors ✦ | 1 | -100.0% | $61 | 0.0% | ▼ Trim | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Marshall Wace | $40.46M | was 0.1% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 805 holders, 201.47M shares, $18.13B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 2.64K sh · $297,780
Officer · 13.98K sh · $1.69M
Officer · 9.23K sh · $1.11M
Officer · 10.80K sh · $1.36M
Officer · 10.80K sh · $1.30M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology